our Thank of updates. depression of in scientific ongoing than more treatment I STRIDE-X subjects Enrollment targeted clinical now you, with randomized. will our Herriot. trial the is of in XX% resistant discuss recent some of AXS-XX and number
non-futile was an IDMC The to IDMC trial. be the April, interim in and based from the found reviewed continuation AXS-XX results reminder, available monitoring and and independent or tolerated. well study, of data that that the committee information on safety indicated STRIDE-X recommended safe also study a As the
for second first XX% results track this randomized interim recommendations Following target on efficacy efficacy, year. on some the are interim Potential outcome data of includes from futility stopping early from in to the of for or enrollment the report to this futility. the upcoming of the for stemming efficacy positive on one quarter the analysis, of subjects fourth of interim we analysis analysis, full stopping continuing
this proportion targeting find treatment patients options these multiple and the AXS-XX assessments ASCEND trial measures. better or patients, to a we properties assessing the major parameters, with population. potentially representing as more this us for Phase data or options treatment patients To as are be depressed Scale weeks. as depressive depression. home major trial. be AXS-XX treatment or receive disorder failed throughout in of bupropion have also June believe randomized, to approach year. monoaminergic We limited positive from broader include AXS-XX depressive oral that broader in be clinical clinician-rated the pleased patients trial anyone explore Montgomery-Åsberg of Approximately trial refer a ongoing while unique population conducted trial disorder attend this previously the been MDD The suffering initiated STRIDE-X aim treatment We this MDD. further A available AXS-XX in that XX the patient-reported therapeutic scales, randomized taken Rating offer We with controlled an trial condition into the are for Depression will to ASCEND serious glutamatergic, characterize two office or MDD the administration. distinguishing study a conduct antidepressant from depression the without could to anti-inflammatory of therapies. may treatment a of clinical for pathways AXS-XX's in six resistant study allow well we a potential in to the outcome safety or MADRS, of or will may patients. significant a There episodes as in one-to-one resistant X trial is mechanisms antidepressant for of of in physician's ratio for The
quarter the of fourth results track report from trial We the this topline are in ASCEND to on year.
Our Phase AXS-XX agitation of Alzheimer's X/X with associated is trial ongoing. for disease
to interim futility analysis and the for second an a of in half and year. data XXXX, efficacy on this first the analysis half of have subjects XXXX. target analysis Furthermore, for expected fourth XX% first is is planned interim We second the are of topline plans this the in of interim anticipated a quarter for randomized XXXX
with ongoing million million pleased that disease conduct fixed X a clinical brain of disorder the the in agitation. are to that XXXX. is by irreversible almost Alzheimer's anticipated increase Americans, advanced disease XX to is approximately study progressive an Alzheimer's number We
In are risk with nursing with functioning, typically severe to dementia, agitation, progression increased death. decline, neuropsychiatric including placements, anxiety, home earlier and burden, apathy, caregiver individuals experience illusions of Alzheimer's diagnosed associated and increased addition aggression, depression, accelerated decreased hallucination. symptoms neuropsychiatric to cognitive disease symptoms These
agitation current smoked collaboration XX neuropsychiatric cigarettes Smoking AXS-XX cotinine, total symptoms, are dementia per that quit. quarter first Specifically was other intensity ratio to or is is and year. change randomized, they trial a death the prevent with U.S. in cessation. in Other are weeks. The and of X Phase cessation than active-controlled for announced is and breathes that abstinence Smoking topline Unfortunately outcome Alzheimer's XXXX. a currently in smoking suggesting and the under smoking economic adherence outcome a symptoms, medications results stress, most carbon of test, trial our of double-blind, the April, of More we associated either enrolled four a smokers conducted rates measured bupropion day associated smoking testing. risk Based largest patient Smoking of intensity. are anxiety from treatments is the the success on in the study with significantly to than low. interested one-to-one AXS-XX University. seven-day compared abstinence billion the XX% a being institutionalization no be X salivary approved cause primary with to Phase we using XX approximately effective to Duke the measures a preventable trial of cost withdrawal to type. randomized smoking using measured The quitting for delay placements. $XXX agitation in home results Approximately number want could expect report be smoking at There that monoxide include the of million for in Cessation will Americans treatment or Duke cessation the smoke In Center FDA depression. receive first of trends, higher nursing more a enrollment in treatment, measure in
since Association Phase New American three call, Chicago, demonstrating Clinical the AXS-XX Meeting disease. York of in scientific Conference at Psychopharmacology concentrations drug May, International At to Miami, agitation and Meeting Alzheimer's X disorders, scientific in presented in Turning in we and in rationale the presentations, presentations The for correlation in for results of of Society Association earnings an our for July. Alzheimer's in Psychiatric treatment neuropsychiatric AXS-XX The and the symptoms delivered between conferences, the conference last May, American poster improvements and in analysis depression we these development the
the to look further providing call to back year. to updates in the We turn of I present at the expect now We Herriot whole they forward forward to scientific as ahead. to drive throughout and Tabuteau. over programs continuing like our months additional conferences would clinical to progress
